TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects

Clinical Immunology

Volumn 132, Issue 1, 2009, Pages 32-42

  Nguyen, Vinh ^a   Cudrici, Cornelia ^a   Zernetkina, Valentina ^a   Niculescu, Florin ^a   Rus, Horea ^a   Drachenberg, Cynthia ^a   Rus, Violeta ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Autoimmunity; ; Lupus nephritis; ; Systemic lupus erythematosus; ; TNF related apoptosis inducing ligand;

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UO 126;

ADULT; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; FEMALE; HUMAN; IN VITRO STUDY; INFLAMMATION; KIDNEY DISTAL TUBULE; KIDNEY EPITHELIUM; KIDNEY PROXIMAL TUBULE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UPREGULATION;

ADOLESCENT; ADULT; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; KIDNEY; KIDNEY TUBULES, PROXIMAL; LUPUS NEPHRITIS; MALE; MIDDLE AGED; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 67349262037     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.02.011     Document Type: Article

References (46)

1. Jeremias I., Herr I., Boehler T., and Debatin K.M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28 (1998) 143-152
2. Morel J., Audo R., Hahne M., and Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 280 (2005) 15709-15718
3. Li J.H., Kirkiles-Smith N.C., McNiff J.M., and Pober J.S. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J. Immunol. 171 (2003) 1526-1533
4. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
5. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., and Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7 (1997) 821-830
6. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 (1996) 12687-12690
7. Ursini-Siegel J., Zhang W., Altmeyer A., Hatada E.N., Do R.K., Yagita H., and Chen-Kiang S. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J. Immunol. 169 (2002) 5505-5513
8. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., and Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003) 2250-2256
9. Lamhamedi-Cherradi S.E., Zheng S., Tisch R.M., and Chen Y.H. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52 (2003) 2274-2278
10. Lamhamedi-Cherradi S.E., Zheng S.J., Maguschak K.A., Peschon J., and Chen Y.H. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat. Immunol. 4 (2003) 255-260
11. Mi Q.S., Ly D., Lamhamedi-Cherradi S.E., Salojin K.V., Zhou L., Grattan M., Meagher C., Zucker P., Chen Y.H., Nagle J., Taub D., and Delovitch T.L. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 52 (2003) 1967-1975
12. Hilliard B., Wilmen A., Seidel C., Liu T.S., Goke R., and Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166 (2001) 1314-1319
13. Kaplan M.J., Lewis E.E., Shelden E.A., Somers E., Pavlic R., McCune W.J., and Richardson B.C. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J. Immunol. 169 (2002) 6020-6029
14. Matsuyama W., Yamamoto M., Higashimoto I., Oonakahara K., Watanabe M., Machida K., Yoshimura T., Eiraku N., Kawabata M., Osame M., and Arimura K. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus. Blood 104 (2004) 184-191
15. Rus V., Zernetkina V., Puliaev R., Cudrici C., Mathai S., and Via C.S. Increased expression and production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients is a feature of active disease. Clin. Immunol. 117 (2005) 48-56
16. Zhou T., Mountz J.D., and Kimberly R.P. Immunobiology of tumor necrosis factor receptor superfamily. Immunol. Res. 26 (2002) 323-336
17. Carter R.H., Pandey S., and Zhou T. Death receptor 5 as a therapeutic target: increased expression in B and T cell subsets in SLE. Clin. Immunol. 115 S1 (2005) S111
18. Kaplan M.J., Ray D., Mo R.R., Yung R.L., and Richardson B.C. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J. Immunol. 164 (2000) 2897-2904
19. Tsai H.F., Lai J.J., Chou A.H., Wang T.F., Wu C.S., and Hsu P.N. Induction of costimulation of human CD4T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 629-639
20. Kayagaki N., Yamaguchi N., Abe M., Hirose S., Shirai T., Okumura K., and Yagita H. Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL). Cell. Immunol. 219 (2002) 82-91
21. Rus V., Nguyen V., Puliaev R., Puliaeva I., Zernetkina V., Luzina I., Papadimitriou J.C., and Via C.S. T cell TRAIL promotes murine lupus by sustaining effector CD4 Th cell numbers and by inhibiting CD8 CTL activity. J. Immunol. 178 (2007) 3962-3972
22. Song C.J., Liu X.S., Zhu Y., Chen L.H., Jia W., Li Y.N., Cao Y.X., Xie X., Zhuang R., Zhu C.S., and Jin B.Q. Expression of TRAIL, DR4, and DR5 in kidney and serum from patients receiving renal transplantation. Transplant. Proc. 36 (2004) 1340-1343
23. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., and Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25 (1982) 1271-1277
24. Weening J.J., D'Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., Balow J.E., Bruijn J.A., Cook T., Ferrario F., Fogo A.B., Ginzler E.M., Hebert L., Hill G., Hill P., Jennette J.C., Kong N.C., Lesavre P., Lockshin M., Looi L.M., Makino H., Moura L.A., and Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15 (2004) 241-250
25. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., and Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35 (1992) 630-640
26. Spierings D.C., de Vries E.G., Vellenga E., van den Heuvel F.A., Koornstra J.J., Wesseling J., Hollema H., and de Jong S. Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem. 52 (2004) 821-831
27. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., and Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189 (1999) 1451-1460
28. Tecchio C., Huber V., Scapini P., Calzetti F., Margotto D., Todeschini G., Pilla L., Martinelli G., Pizzolo G., Rivoltini L., and Cassatella M.A. IFN{alpha}-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 103 (2004) 3837-3844
29. Ehrlich S., Infante-Duarte C., Seeger B., and Zipp F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 24 (2003) 244-253
30. Boswell J.M., Yui M.A., Burt D.W., and Kelley V.E. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J. Immunol. 141 (1988) 3050-3054
31. Masutani K., Akahoshi M., Tsuruya K., Tokumoto M., Ninomiya T., Kohsaka T., Fukuda K., Kanai H., Nakashima H., Otsuka T., and Hirakata H. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 44 (2001) 2097-2106
32. Aringer M., and Smolen J.S. Cytokine expression in lupus kidneys. Lupus 14 (2005) 13-18
33. Asakuma J., Sumitomo M., Asano T., and Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res. 63 (2003) 1365-1370
34. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., and Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22 (2003) 3842-3852
35. Herrera-Esparza R., Barbosa-Cisneros O., Villalobos-Hurtado R., and Avalos-Diaz E. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus 7 (1998) 154-158
36. Takemura T., Yoshioka K., Murakami K., Akano N., Okada M., Aya N., and Maki S. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch. 424 (1994) 459-464
37. Griffith T.S., Fialkov J.M., Scott D.L., Azuhata T., Williams R.D., Wall N.R., Altieri D.C., and Sandler A.D. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res. 62 (2002) 3093-3099
38. Lange-Sperandio B., Fulda S., Vandewalle A., and Chevalier R.L. Macrophages induce apoptosis in proximal tubule cells. Pediatr. Nephrol. 18 (2003) 335-341
39. Khan S., Koepke A., Jarad G., Schlessman K., Cleveland R.P., Wang B., Konieczkowski M., and Schelling J.R. Apoptosis and JNK activation are differentially regulated by Fas expression level in renal tubular epithelial cells. Kidney Int. 60 (2001) 65-76
40. Tran S.E., Holmstrom T.H., Ahonen M., Kahari V.M., and Eriksson J.E. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276 (2001) 16484-16490
41. Muhlenbeck F., Haas E., Schwenzer R., Schubert G., Grell M., Smith C., Scheurich P., and Wajant H. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J. Biol. Chem. 273 (1998) 33091-33098
42. Soderstrom T.S., Poukkula M., Holmstrom T.H., Heiskanen K.M., and Eriksson J.E. Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J. Immunol. 169 (2002) 2851-2860
43. Zauli G., Sancilio S., Cataldi A., Sabatini N., Bosco D., and Di Pietro R. PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment. J. Cell. Physiol. 202 (2005) 900-911
44. Miyashita T., Kawakami A., Tamai M., Izumi Y., Mingguo H., Tanaka F., Abiru S., Nakashima K., Iwanaga N., Aratake K., Kamachi M., Arima K., Ida H., Migita K., Origuchi T., Tagashira S., Nishikaku F., and Eguchi K. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem. Biophys. Res. Commun. 312 (2003) 397-404
45. Daniel L., Sichez H., Giorgi R., Dussol B., Figarella-Branger D., Pellissier J.F., and Berland Y. Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int. 60 (2001) 2215-2221
46. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., Zhang H., Mountz J.D., Koopman W.J., Kimberly R.P., and Zhou T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7 (2001) 954-960